Prem S. Shah - 16 Feb 2024 Form 4 Insider Report for CVS HEALTH Corp (CVS)

Role
EVP and Pres-Pharm, Consumer W
Signature
/s/ Prem S. Shah
Issuer symbol
CVS
Transactions as of
16 Feb 2024
Net transactions value
-$2,267,947
Form type
4
Filing time
16 Feb 2024, 18:46:48 UTC
Previous filing
14 Feb 2024
Next filing
28 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CVS Common Stock Sale $2,267,947 -29,473 -43% $76.95 39,765 16 Feb 2024 Direct F1
holding CVS Common Stock (Restricted) 29,649 16 Feb 2024 Direct
holding CVS ESOP Common Stock 4,789 16 Feb 2024 Direct
holding CVS Stock Unit (deferred) 3,350 16 Feb 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CVS Phantom Stock Credits 33,755 16 Feb 2024 Common Stock 33,755 $1.00 Direct F3, F4
holding CVS Stock Option 846 16 Feb 2024 Common Stock 846 $62.21 Direct F5
holding CVS Stock Option 9,469 16 Feb 2024 Common Stock 9,469 $54.19 Direct F6
holding CVS Stock Option 28,596 16 Feb 2024 Common Stock 28,596 $58.34 Direct F7
holding CVS Stock Option 26,580 16 Feb 2024 Common Stock 26,580 $75.24 Direct F8
holding CVS Stock Option 28,723 16 Feb 2024 Common Stock 28,723 $74.30 Direct F9
holding CVS Stock Option 41,580 16 Feb 2024 Common Stock 41,580 $101.09 Direct F10
holding CVS Stock Option 89,073 16 Feb 2024 Common Stock 89,073 $74.31 Direct F11
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents weighted average sale price for this group of sales, which occurred on the same trading day. Multiple sales were executed, with sales prices ranging between 76.93 to 76.99 per share.
F2 Consists of Stock Units awarded pursuant to Issuer's 2010 & 2017 Incentive Compensation Plans, the receipt of which the reporting person has elected to defer.
F3 Reflects year-end company-match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.
F4 Reflects year-end company-match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.
F5 Option became exercisable in four equal installments commencing 04/01/2019. Additional options from this award have been exercised.
F6 Option became exercisable in four equal installments commencing 04/01/2020. Additional options from this award have been exercised
F7 Option became exercisable in four equal installments commencing 04/01/2021. Additional options from this award have been exercised.
F8 Option became exercisable in three equal installments, commencing on 8/31/2021.
F9 Option became exercisable in three equal installments commencing 04/01/2022.
F10 Option became exercisable in four equal installments, commencing 4/1/2023.
F11 Option becomes exercisable in four equal annual installments, commencing 4/1/2024.